Skip to search formSkip to main contentSkip to account menu
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
View on Elsevier
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
TLDR
Elevation of ADMA is associated with impaired endothelium-dependent vasodilation and reduced urinary nitrate excretion and this abnormality is reversed by administration of L-arginine.
View on PubMed
LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases.
TLDR
The data suggest that the production of ADMA by human endothelial cells is regulated by S-adenosylmethionine-dependent methyltransferases, which may be due in part to the enhanced gene expression of PRMTs.
View on PubMed
The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio.
View on PubMed
Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.
TLDR
In PAOD patients, there is a progressive reduction in urinary nitrate and cGMP excretion rates, which may be caused in part by accumulation of ADMA, an endogenous inhibitor of NO synthase.
View on PubMed
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
TLDR
Lowering plasma ADMA concentrations may be a novel therapeutic target to prevent progressive renal impairment in patients with nondiabetic kidney diseases.
View on PubMed
Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease.
TLDR
It is concluded that SDMA might be a useful parameter for detecting patients in very early stages of chronic kidney disease and for determining their risk for developing cardiovascular disease.
View on PubMed
L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship.
TLDR
The vasodilator effect of L-arginine and its effects on endogenous NO production closely corresponded to the plasma concentration half-life of L -arginne, as indicated by an equilibration half- life of 6+/-2 (3.7-8.4) min between plasma concentration and effect in pharmacokinetic-pharmacodynamic analysis, and the lack of hysteresis in the Plasma concentration-versus-effect plot.
View on PubMed
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
TLDR
In contrast to several traditional cardiovascular risk factors, markedly increased blood concentrations of ADMA, a putative biochemical marker of atherosclerosis, are present even in nonsmoking patients without diabetes with incipient primary renal disease, and may be of relevance for the excess cardiovascular morbidity and mortality due to arterio- and atherosclerotic complications in patients with renal disease.
View on PubMed
Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
TLDR
Because ADMA acts as a competitive inhibitor of endothelial nitric oxide synthase, these findings suggest a novel mechanism for impaired endothelial function in hyperhomocyst(e)inemia.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License